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Effect of oral melatonin on the procoagulant response to acute
psychosocial stress in healthy men: a randomized
placebo-controlled study
Abstract
Acute mental stress is a potent trigger of acute coronary syndromes. Catecholamine-induced
hypercoagulability with acute stress contributes to thrombus growth after coronary plaque rupture.
Melatonin may diminish catecholamine activity. We hypothesized that melatonin mitigates the acute
procoagulant stress response and that this effect is accompanied by a decrease in the stress-induced
catecholamine surge. Forty-five healthy young men received a single oral dose of either 3 mg melatonin
(n = 24) or placebo medication (n = 21). One hour thereafter, they underwent a standardized short-term
psychosocial stressor. Plasma levels of clotting factor VII activity (FVII:C), FVIII:C, fibrinogen,
D-dimer, and catecholamines were measured at rest, immediately after stress, and 20 min and 60 min
post-stress. The integrated change in D-dimer levels from rest to 60 min post-stress differed between
medication groups controlling for demographic and metabolic factors (P = 0.047, eta(p)(2) = 0.195).
Compared with the melatonin group, the placebo group showed a greater increase in absolute D-dimer
levels from rest to immediately post-stress (P = 0.13; eta(p)(2) = 0.060) and significant recovery of
D-dimer levels from immediately post-stress to 60 min thereafter (P = 0.007; eta(p)(2) = 0.174).
Stress-induced changes in FVII:C, FVIII:C, fibrinogen, and catecholamines did not significantly differ
between groups. Oral melatonin attenuated the stress-induced elevation in the sensitive coagulation
activation marker D-dimer without affecting catecholamine activity. The finding provides preliminary
support for a protective effect of melatonin in reducing the atherothrombotic risk with acute mental
stress.
 1 
EFFECT OF ORAL MELATONIN ON THE PROCOAGULANT RESPONSE TO 
ACUTE PSYCHOSOCIAL STRESS IN HEALTHY MEN: 
A RANDOMIZED PLACEBO-CONTROLLED STUDY  
 
Running title: Melatonin and the procoagulant stress response 
 
1 Petra H. Wirtz, 1 Carmen Bärtschi, 1 Maria Spillmann, 1 Ulrike Ehlert, and 2 Roland von 
Känel 
 
1
 Department of Clinical Psychology and Psychotherapy, University of Zurich, Switzerland 
2
 Department of General Internal Medicine, University Hospital Bern, Switzerland 
 
 
Corresponding author: 
Roland von Känel, M.D. 
Professor of Medicine & Head Division of Psychosomatic Medicine 
Department of General Internal Medicine 
University Hospital / INSELSPITAL 
CH-3010 Bern / Switzerland 
Tel. +41 31 632 20 19; Fax +41 31 382 11 84; E-mail: roland.vonkaenel@insel.ch 
 
 
Key words: cardiovascular disease, coagulation, hemostasis, melatonin, psychological stress 
 2 
SUMMARY 
Acute mental stress is a potent trigger of acute coronary syndromes. Catecholamine-
induced hypercoagulability with acute stress contributes to thrombus growth after coronary 
plaque rupture. Melatonin may diminish catecholamine activity. We hypothesized that 
melatonin mitigates the acute procoagulant stress response and that this effect is accompanied 
by a decrease in the stress-induced catecholamine surge. Forty-five healthy young men 
received a single oral dose of either 3 mg melatonin (n=24) or placebo medication (n=21). 
One hour thereafter, they underwent a standardized short-term psychosocial stressor. Plasma 
levels of clotting factor VII activity (FVII:C), FVIII:C, fibrinogen, D-dimer, and 
catecholamines were measured at rest, immediately after stress, and 20 min and 60 min post-
stress. The integrated change in D-dimer levels from rest to 60 min post-stress differed 
between medication groups controlling for demographic and metabolic factors 
(p=0.047,ηp2=0.195). Compared to the melatonin group, the placebo group showed a greater 
increase in absolute D-dimer levels from rest to immediately post-stress (p=0.13;ηp2=0.060) 
and significant recovery of D-dimer levels from immediately post-stress to 60 min thereafter 
(p=0.007;ηp2=0.174). Stress-induced changes in FVII:C, FVIII:C, fibrinogen, and 
catecholamines did not significantly differ between groups. Oral melatonin attenuated the 
stress-induced elevation in the sensitive coagulation activation marker D-dimer without 
affecting catecholamine activity. The finding provides preliminary support for a protective 
effect of melatonin in reducing the atherothrombotic risk with acute mental stress. 
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INTRODUCTION 
Acute mental stress has been identified as an important trigger of acute coronary 
syndromes (ACS) [1-3]. After rupture of an atherosclerotic coronary plaque, the balance 
between prothrombotic and antithrombotic forces in the circulation determines the extent of 
intracoronary thrombus growth and consequent myocardial damage [4]. Catecholamine surge 
that accompanies triggering events may increase the risk of plaque thrombosis [2] since an 
acute systemic increase in catecholamines evokes a hypercoagulable state [5]. Particularly, 
epinephrine infusion to healthy individuals activates platelets and increases plasma levels of 
factor VIII coagulant activity (FVIII:C) and of hemostatically active von Willebrand factor 
[5]. Also, the magnitude of norepinephrine surge during acute mental stress was directly 
associated with increases in thrombin/antithrombin III complex (i.e. a marker of thrombin 
formation) [6] and D-dimer (i.e. a marker of fibrin formation) [7]. Acute mental stress was 
also shown to elicit an increase in plasma levels of factor VII coagulant activity (FVII:C) and 
fibrinogen [8]. Together with tissue factor exposed to the blood stream at sites of endothelial 
lesions, FVII initiates the extrinsic pathway of blood coagulation, ultimately leading to a 
fibrin clot further downstream in the coagulation cascade. During this process, thrombin 
activates FVIII and converts fibrinogen to fibrin [9]. 
Melatonin is a substance with pleiotropic physiological actions synthesized in the 
pineal gland [10]. With regard to the emerging function of melatonin in cardiovascular 
disease [11], nocturnal secretion of melatonin was lower in patients with coronary artery 
disease, particularly in those with ACS, than in healthy controls [12-15]. Research suggests 
that exogenous administration of supraphysiological melatonin dosages might favourably 
affect inflammatory and prothrombotic mechanisms pertinent to the manifestation of ACS. In 
animal models, melatonin reduced leukocyte rolling and adhesion in the microcirculation 
during acute inflammation [16] and normalized shortened prothrombin time and elevated 
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levels of fibrin degradation products inflicted by thermal injury [17]. Melatonin infusion also 
reduced arrhythmias induced by experimental ischemia of the isolated rat heart [18]. In 
humans, platelet aggregation in vitro was inhibited by melatonin suggesting a dose-response 
effect [19, 20]. Importantly, placebo-controlled studies found decreased plasma levels of 
norepinephrine 60 min after intake of 2 mg melatonin in healthy young men [21] and 5 min 
after intake of 1 mg melatonin in healthy young women [22] and men [23], respectively. 
To our knowledge, it has not been investigated whether exogenous melatonin affects 
coagulation and catecholamine responses to acute mental stress. The above research suggests 
that oral melatonin could mitigate the procoagulant response to acute mental stress and that 
such an effect could be a consequence of reduced catecholamine activity during stress with 
melatonin medication. To test this hypothesis, we subjected a sample of young and healthy 
men to a standardized acute psychosocial stressor after they had received either oral 
melatonin or placebo medication. We specifically hypothesized that the integrated, stress-
induced increase in plasma levels of FVII:C, FVIII:C, fibrinogen, and D-dimer from rest to 
60 min post-stress is smaller with melatonin than with placebo. We controlled for age, body 
mass index (BMI), screening blood pressure (BP) and heart rate (HR) – as a proxy measure 
of vagal tone – since these variables may affect hemostatic activity in healthy subjects [24-
27]. We further hypothesized that, in the melatonin group, attenuation of the procoagulant 
stress response is paralleled by a decrease in the catecholamine response to stress.  
 
MATERIALS AND METHODS 
Participants and study design 
The study protocol was formally approved by the ethics committee of the State of 
Zurich, Switzerland, and by Switzerland’s regulatory agency for therapeutic products 
(Swissmedic). The study was carried out in accordance with the Declaration of Helsinki 
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principles. All participants provided written informed consent. We report on 45 medication-
free healthy young men, all non-smokers, with a complete data set in terms of coagulation 
and catecholamine measures. Subjects with any self-reported acute or chronic somatic or 
psychiatric disorder were not eligible for the study. Specific exclusion criteria were regular 
strenuous exercise, alcohol abuse and illicit drug use, heart disease, elevated blood sugar and 
diabetes, elevated cholesterol, liver and renal diseases, chronic obstructive pulmonary 
disease, allergies and atopic diathesis, rheumatic diseases, and current infectious diseases. We 
contacted the subjects’ primary care physician if the history was not conclusive.  
All subjects were scheduled on two consecutive days. They abstained from food and 
drink other than water for two hours before reporting to the laboratory and from physical 
exercise and consumption of alcohol and caffeinated beverages starting the evening before 
day 1. On day 1, after subjects had been sitting quietly for 20 minutes, screening BP and HR 
were measured once using the fully automated Omron device (Omron 773, Omron 
Medizintechnik Handelsgesellschaft mbH, Mannheim, Germany). The BMI was calculated 
by dividing the weight in kilograms by the square of height in meters (kg/m2). On day 2, 
testing sessions commenced between 14:00 h and 16:00 h. A venous catheter was placed and 
25 min thereafter subjects were randomized, single-blinded, to one oral pill of either 3 mg 
melatonin or placebo. Melatonin was purchased from Physiologics (“Melatonin Standard”, 
PhysioLogics, Northglenn, CO, USA). Placebo pills contained lactosis and amylum (lactosi 
cum amylo) and were purchased from Hänseler AG (Herisau, Switzerland).  
 
Stress experiment 
Following previous observations on melatonin kinetics after oral intake of 1-5 mg of 
melatonin, subjects underwent the psychosocial stressor 60 min after intake of the 
medication, when blood levels of melatonin are expected to peak [28, 29]. We presumed that 
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melatonin exerted physiological effects during the entire stress experiment since exogenously 
increased melatonin levels return to baseline values only within four to eight hours [10]. 
We applied the standard protocol of the widely used Trier Social Stress Test (TSST), 
which combines a short introduction phase followed by a 5-minute preparation phase, a 5-
minute mock job interview, and a 5-minute mental arithmetic task in front of an audience 
[30]. The TSST evokes reliable increases in the coagulation measures investigated in the 
present study and in plasma catecholamines [7, 8]. During the 60-min recovery from the 
stressor, subjects remained seated in a quiet room. Blood samples for coagulation and 
catecholamine measures were collected at rest, immediately post-stress, and 20 min and 60 
min thereafter. BP and HR were measured at rest and immediately post-stress using the 
Omron device. Data were missing for BP in five subjects and for HR in one subject. 
 
Biochemical analyses 
For coagulation measurements, 4.5 ml of blood was added to 0.5 ml of citrate, 0.106 
Mol/L. Samples were immediately centrifuged for 20 min at 3000 x g at room temperature. 
Plasma aliquots were frozen at -80°C in polypropylene test tubes pending further analysis. 
FVII:C and FVIII:C were determined by standard coagulometric methods using factor-
deficient standard human plasma and reagents (Dade Behring, Liederbach, Germany). 
Fibrinogen was quantified as per a modified Clauss method [31] and D-dimer levels by use of 
an enzyme-linked immunosorbent assay (Asserachrom Stago, Asnières, France). For the 
determination of plasma catecholamine and melatonin concentration, blood was drawn into 
EDTA-coated monovettes (Sarstedt, Numbrecht, Germany) and immediately centrifuged for 
10 min at 2,000 x g at 4º C; plasma was stored at –80°C until analysis. Epinephrine and 
norepinephrine levels were determined by means of high-performance liquid chromatography 
and electrochemical detection after liquid–liquid extraction [32]. Melatonin was extracted 
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with methylene chloride and analysed with a reversed phase HPLC with fluorescence 
detection [33]. The lower limit of detection (LOD) for the melatonin concentration was 2.5 
pg/mL. Samples with a melatonin concentration below the LOD were set at half the LOD (i.e. 
1.25 pg/ml) following previous recommendation for a skewed data set [34]. Inter- and intra-
assay coefficients of variation were <10% for all biochemical analyses (i.e. hemostatic 
factors, melatonin, catecholamines).  
 
Statistical analysis 
SPSS version 13.0 for Windows was used to analyze the data. Significance level was 
set at p<0.05 (two-tailed). Normal distribution of data was tested by the Kolmogorov-
Smirnov test. In order to approximate a normal distribution, the values of FVIII:C, D-dimer, 
epinephrine and melatonin were log transformed. Data are given as means or geometric 
means (for log transformed variables) with SD in the text and with SEM in the tables and 
figures. Student’s t-test was used to calculate differences in variables between two groups. 
Pearson correlation analysis was applied to estimate the bivariate correlation coefficient 
between two variables. Partial correlation analysis was used to control bivariate correlations 
for covariates. 
As sphericity was violated in our data set, we applied multivariate repeated measures 
analysis of covariance (MANCOVA) to test whether stress-induced changes in coagulation 
and catecholamine measures would differ between the melatonin and placebo group 
controlling for covariates. The four time points (i.e. rest, immediately post-stress, 20 min 
post-stress, and 60 min post-stress) were treated as the within-subjects variables and the 
medication group (i.e. melatonin or placebo) as the between-subjects factor. Roy’s largest 
root criterion was applied to test the significance of the multivariate test statistics. The 
number and type of covariates (i.e. age, BMI, BP, HR) were selected a priori given our 
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sample size [35] and based on the previous literature on variables possibly affecting 
hemostatic function [24-27]. In order to preserve degrees of freedom [35], the screening 
mean arterial pressure (MAP) was computed by the formula (2/3* systolic BP plus 1/3* 
systolic BP) and included as a control variable in the analysis. We also controlled for resting 
levels of coagulation and catecholamines measures to account for potential differences 
between medication groups. Differences in resting levels of these parameters could unduly 
inflate a floor (i.e. resting level is comparably low) or ceiling (i.e. resting level is comparably 
high) effect in the stress response of coagulation and catecholamine measures. Effect sizes of 
the repeated measures MANCOVA are expressed as partial eta squared (ηp2). Post hoc 
analysis applied Fisher’s least significant difference. 
 
RESULTS 
Table 1 shows that age, BMI, BP, and HR were not significantly different between 
groups. 
 
Plasma levels of coagulation and catecholamine measures were determined one hour 
after intake of either placebo or melatonin corresponding to resting levels with regard to the 
stress experiment. At this time, plasma melatonin levels were expectedly higher in subjects 
who received melatonin than in those who received placebo medication (140.9±386.0 pg/mL 
vs. 1.7±1.6 pg/mL, p<0.001). Of note, the absolute plasma melatonin levels showed a wide 
range in subjects who had received melatonin (17.3-2046.4 pg/mL) as opposed to those who 
had received placebo (1.3-8.6 pg/mL). 
Catecholamine levels were not significantly different between the two medication 
groups and showed no significant correlation with melatonin levels. As previously reported 
[36], resting FVIII:C levels were significantly lower in subjects who had received melatonin 
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than in those who had received placebo (82.1±32.8 % vs. 101.1 ± 42.0 %; p=0.048). There 
was also a trend towards statistical significance for lower resting fibrinogen levels in the 
melatonin group compared to the placebo group (1.98±0.29 g/L vs. 2.20±0.50 g/L; p<0.08). 
Melatonin levels correlated with FVIII:C levels (r=-0.31, p=0.036) but not significantly so 
with any other coagulation measure.  
 
Table 2 presents the crude changes in hemodynamic indices, catecholamines, and 
coagulation measures from rest to immediately post-stress across all subjects. There was a 
significant increase in all hemodynamic measures and both catecholamines. Also, FVII:C, 
FVIII:C, and fibrinogen significantly increased in response to the TSST with a similar trend 
towards statistical significance observed for D-dimer. Altogether, these data verify that the 
TSST provoked a robust biological stress response. 
 
Figure 1 shows that the integrated change in epinephrine and norepinephrine across 
all time points was not significantly different between groups controlling for catecholamine 
level at rest, age, BMI, MAP, and HR. This suggests that melatonin did not affect the 
response in catecholamine levels to stress and the recovery of catecholamine levels from 
stress differently from placebo medication.  
 
Figure 2 (Panels A-C) shows that the integrated change in FVII:C, FVIII:C, and 
fibrinogen levels between rest and 60 min post-stress was not significantly different between 
medication groups controlling for coagulation factor levels at rest, age, BMI, MAP, and HR. 
This suggests that melatonin affected neither the immediate response in these coagulation 
factors to stress nor the recovery of coagulation factor levels from stress differently from 
placebo medication.  
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In contrast, there was a significant interaction between time and medication for D-
dimer levels controlling for resting D-dimer level, age, BMI, MAP; and HR (F3,36=2.92, 
p=0.047; ηp2=0.195). Figure 2 (Panel D) illustrates that the integrated generation of D-dimer 
from immediately pre-stress to 60 min thereafter was significantly greater in the placebo 
group than in the melatonin group. Post hoc analysis controlled for resting D-dimer level, 
age, BMI, MAP, and HR; it revealed an absolutely greater increase in D-dimer levels from 
rest to immediately post-stress (p=0.13; ηp2=0.060) with a significant recovery from 
immediately post-stress to 60 min thereafter in the placebo group relative to the melatonin 
group (p=0.007; ηp2=0.174). 
 
We recalculated the above repeated measures MANCOVA replacing medication 
group as the between-subjects factor by absolute levels of plasma melatonin as a covariate. 
Melatonin levels were not significantly associated with the integrated change in plasma levels 
of epinephrine (p=0.54), norepinephrine (p=0.39), FVII:C (p=0.87), FVIII:C (p=0.61), and 
fibrinogen (p=0.87) controlling for the respective levels of coagulation measures and 
catecholamines at rest, age, BMI, MAP, and HR.  
There was a trend towards statistical significance for an association between 
melatonin level and the integrated change in D-dimer levels from rest to 60 min post-stress 
(F3,36=2.60, p<0.07; ηp2=0.178) controlling for D-dimer at rest, age, BMI, MAP, and HR. 
Post hoc analysis, also controlling for these covariates, revealed an association between 
melatonin level and D-dimer change from rest to immediately post-stress (r=-0.29, p<0.07), 
from immediately post-stress to 60 min thereafter (r=-0.35, p=0.025),  and also from 20 min 
after stress to 60 min post-stress (r=-0.32. p=0.046). No such significant associations were 
observed in either medication group alone. 
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DISCUSSION 
Consistent with previous studies in other samples, we found that the TSST provoked a 
significant stress response in coagulation measures and catecholamines [6-8] suggesting our 
protocol was suitable to test our hypotheses. In this randomized, placebo-controlled 
experimental study, we found some evidence for our primary hypothesis that melatonin, in an 
exogenously administered supraphysiological dose, attenuates the procoagulant response to 
acute psychosocial stress in humans. Independent of demographic and metabolic covariates, 
the integrated change in D-dimer from rest to one hour after stress was significantly lower in 
the melatonin group than in the placebo group. Although not reaching statistical significance, 
the absolute increase in D-dimer from rest to immediately post-stress was greater with 
placebo than with melatonin. This immediate D-dimer increase was mirrored by a 
significantly greater decrease in D-dimer levels in the placebo group relative to the melatonin 
group during the recovery phase from immediately post-stress to one hour thereafter. This 
observation was confirmed when testing for an association between absolute levels of plasma 
melatonin and stress-induced D-dimer change; i.e. the lower the plasma melatonin level one 
hour after intake of the medication, the greater the increase in D-dimer from rest to 
immediately post-stress and the greater the subsequent decrease in D-dimer during the 
recovery period from stress. Altogether this suggests that subjects who received placebo had 
significantly greater fibrin formation during acute stress and the subsequent recovery phase of 
one hour than subjects who received melatonin. Moreover, there might be an inverse dose-
response relationship between plasma melatonin level and D-dimer formation with stress. 
Noteworthy, the dispersion of plasma melatonin levels in subjects who received melatonin 
was high. This could perhaps be a consequence of differences in metabolic clearance between 
subjects. Future studies may want to investigate the extent to which individual clearance of 
melatonin might affect the procoagulant response to acute stress. 
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D-dimer is a marker of coagulation activation indicating both fibrin formation and its 
subsequent degradation by the fibrinolytic system [37]. In stress experiments, elevated D-
dimer levels in plasma indicate that the entire coagulation system has been activated during 
stress [38]. As opposed to elevated activity levels of individual clotting factors, coagulation 
activation markers are more sensitive to a hypercoagulable state [39]. This could be an 
explanation for why we did not find a significant difference between the melatonin and 
placebo group in terms of their stress responses in FVII:C, FVIII:C, and fibrinogen. Thus, 
supraphysiological melatonin dosages might attenuate the procoagulant stress response in 
vivo at different and likely subtle levels throughout the entire coagulation and fibrinolysis 
pathways rather than overtly at the level of individual hemostatic factors. We acknowledge, 
however, that we did not measure platelet activity previously shown to be inhibited by 
melatonin in vitro [19, 20]. Therefore, we are unable to discount the possibility that the 
decreased D-dimer change to stress with melatonin was largely a consequence of platelet 
inhibition. Moreover, we did not measure body temperature, which has been shown to 
decrease in a dose-dependent manner within 30 to 60 minutes after administration of 
melatonin dosages between 1 mg and 5 mg [40]. Also, although not investigated in our study, 
acute mental stress reliably increases tissue-plasminogen activator activity, thereby enhancing 
fibrinolytic activity [41]. Fibrinolytic activity in vitro was found to be reduced when t-PA is 
relatively high and when body temperature is relatively low [42]. The attenuated D-dimer 
formation in our subjects who received melatonin could therefore reflect relatively attenuated 
fibrinolytic activity and consequently less fibrin degradation with acute stress due to 
melatonin-induced lowering of body temperature. 
Rupture of a coronary plaque and subsequent thrombosis marks the core transition 
from stable coronary artery disease to ACS [4]. Previous studies reported higher D-dimer 
concentrations in ACS than for control subjects reflecting that D-dimer is a plasma marker of 
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activated hemostasis in the early phase of ACS [43]. Increased D-dimer concentration during 
admission for ACS predicted major adverse cardiac events during hospitalization [44]. The 
coagulation activation by stress adds to the prothrombotic state initiated by plaque rupture 
thereby arguably increasing the overall risk of clinical manifestation of ACS [41, 45]. Hence, 
our data suggest that the blunting effect of melatonin on the procoagulant response to acute 
psychosocial stress is clinically meaningful. Indeed, medication explained almost 20% of the 
variance in stress-induced D-dimer change. An anticoagulant effect of melatonin would also 
concur with a previous study showing that melatonin infusion reduced ischemic 
complications after experimentally induced myocardial ischemia in the isolated rat heart [18]. 
In our subjects, melatonin did not affect the catecholamine response to acute 
psychosocial stress differently from placebo. Therefore the present study does not support our 
secondary hypothesis that reduced D-dimer formation in the melatonin group was mediated 
by attenuated catecholamine activity. In contrast to other placebo-controlled studies on 
healthy young men [21, 23], we did not observe lower plasma norepinephrine levels in the 
melatonin group compared to the placebo group one hour after intake of the medication. This 
could be because we obtained blood for catecholamine measurements while subjects were 
sitting, whereas previous studies found an effect of melatonin on plasma norepinephrine 
levels only when subjects were supine [21-23]. Also, subjects were relaxed in previous 
studies, so anticipatory arousal before the experiment could have blurred a group difference 
in our subjects. However, we feel it is premature to definitely conclude that melatonin does 
not exert anticoagulant properties during stress by reducing catecholamine activity. 
The randomized, placebo-controlled design and application of a standardized stress 
protocol provoking reliable biological stress responses were strengths of our study. 
Moreover, our study design likely prevented biasing of D-dimer findings by diurnal 
variations in circulating D-dimer levels [46]. Our data cannot be generalized to women, 
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elderly subjects, and patients with coronary artery disease who are the at-risk population for 
ACS. However, it seemed prudent to first investigate the effect of melatonin on coagulation 
activation with stress in a healthy young population before subjecting patients with 
cardiovascular diseases to a study medication (i.e. melatonin) that has not been approved by 
Switzerland’s regulatory agency for therapeutic products. Because we were unable to confirm 
a catecholamine hypothesis explaining attenuated coagulation activity with stress after 
melatonin administration, the mechanisms by which melatonin may decrease the acute 
procoagulant stress response are subject to future studies. For instance, markers of a 
hypercoagulable state may also reflect the endogenous anticoagulant properties of the 
vascular endothelium [39]. Melatonin and several of its metabolites have antioxidative 
properties and the capacity to regulate vascular tone, both of which alone or in combination 
might relate to endothelial anticoagulant function [10, 47-53]. 
Taken together, we found that a single dose of oral melatonin attenuated the stress-
induced change in plasma D-dimer levels relative to placebo. Although the stress reactivity of 
individual clotting factors was not affected by melatonin, our data lend some support to the 
hypothesis that melatonin might mitigate overall activation of the coagulation system (i.e. 
fibrin turnover) during stress. Because melatonin did not attenuate catecholamine reactivity, 
the physiological mechanisms involved in the anticoagulant effect of melatonin during stress 
are currently speculative. It also remains to be determined whether melatonin may alleviate 
the increased risk of ACS with acute mental stress. 
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Table 1. Characteristics of the 45 men studied. 
 
    
Variable  Melatonin (n=24) Placebo (n=21) P-value 
    
Age [yrs] 24.3 ± 0.7 25.1 ± 0.8 0.446 
Body mass index [kg/m2] 23.0 ± 0.6 22.7 ± 0.4 0.683 
Mean arterial pressure [mmHg] 
 Systolic blood pressure [mmHg] 
 Diastolic blood pressure [mmHg] 
94.1 ± 1.7 
127.8 ± 3.0 
77.3 ± 1.6 
94.7 ± 2.2 
124.8 ± 2.6 
79.7 ± 2.3 
0.828 
0.459 
0.390 
Heart rate [bpm] 72.0 ± 2.3 65.6 ± 2.5 0.068 
 
Values are given as means ± SEM; group comparison was by Student’s t-test 
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Table 2. Immediate change in biological measures with stress across all subjects. 
     
Measures N Rest Post-stress P-value 
     
Systolic blood pressure [mmHg] 40 113.0±2.1 126.1±1.8 <0.001 
Diastolic blood pressure [mmHg] 40 70.9±1.4 80.6±1.4 <0.001 
Heart rate [bpm] 44 69.8±2.0 82.8±2.3 <0.001 
Epinephrine [pg/mL] 45 23.0±2.3 37.7±3.5 <0.001 
Norepinephrine [pg/mL] 45 340.8±19.6 557.1±30.7 <0.001 
Factor VII:C [%] 45 85.6±2.5 89.9±2.5 <0.001 
Factor VIII:C [%] 45 90.6±4.9 97.2±5.1 0.001 
Fibrinogen [g/L] 45 2.08±0.06 2.24±0.06 <0.001 
D-dimer [ng/mL] 45 123.4±9.7 130.8±10.0 0.058 
 
Values are given as geometric means ± SEM for epinephrine, factor VIII:C, and D-dimer and 
as means ± SEM for all other measures.  
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LEGENDS TO FIGURES 
Fig. 1. The stress response in both catecholamines was not significantly different between the 
melatonin and placebo group. All analyses controlled for catecholamine level at rest, age, 
body mass index, mean arterial blood pressure and heart rate. Values are given as geometric 
means ± SEM for epinephrine (A) and as means ± SEM for norepinephrine (B). 
 
Fig. 2. The stress response in D-dimer (D) was significantly different between the melatonin 
group and the placebo group, whereas the stress response in factor VII:C (A), factor VIII:C 
(B), and in fibrinogen (C) did not significantly differ between groups. All analyses controlled 
for coagulation factor level at rest, age, body mass index, mean arterial blood pressure and 
heart rate. Values are given as means ± SEM for factor VII:C and fibrinogen and as 
geometric means for factor VIII:C and D-dimer. 
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Figure 1. Stress response in catecholamine measures 
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Figure 2. Stress responses of coagulation measures 
 
 
 
 
 
